During the 2012 American Neurological Association Annual Meeting in Boston,researchers announced on Monday that solanezumab, developed by Eli Lilly, showed a 34% improvement in cognitive skills, like memory, however, only slight improvement in daily functions in patients with mild cases of Alzheimer’s.  The medication blocks beta amyloid, a protein that forms plaque on the brain and investigators are encouraged these results may lead to future research of this protein.  What medications are currently used in the treatment of Alzheimer’s disease?

For more information, please read the article in Reuters.